Integral Diagnostics Limited
Integral Diagnostics Limited Fundamental Analysis
Integral Diagnostics Limited (IDX.AX) shows weak financial fundamentals with a PE ratio of 59.78, profit margin of 1.83%, and ROE of 2.05%. The company generates $0.8B in annual revenue with strong year-over-year growth of 33.54%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze IDX.AX's fundamental strength across five key dimensions:
Efficiency Score
WeakIDX.AX struggles to generate sufficient returns from assets.
Valuation Score
ModerateIDX.AX shows balanced valuation metrics.
Growth Score
ModerateIDX.AX shows steady but slowing expansion.
Financial Health Score
WeakIDX.AX carries high financial risk with limited liquidity.
Profitability Score
ModerateIDX.AX maintains healthy but balanced margins.
Key Financial Metrics
Is IDX.AX Expensive or Cheap?
P/E Ratio
IDX.AX trades at 59.78 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, IDX.AX's PEG of 0.28 indicates potential undervaluation.
Price to Book
The market values Integral Diagnostics Limited at 1.24 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.24 times EBITDA. This is generally considered low.
How Well Does IDX.AX Make Money?
Net Profit Margin
For every $100 in sales, Integral Diagnostics Limited keeps $1.83 as profit after all expenses.
Operating Margin
Core operations generate 9.18 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.05 in profit for every $100 of shareholder equity.
ROA
Integral Diagnostics Limited generates $0.99 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Integral Diagnostics Limited produces operating cash flow of $84.50M, showing steady but balanced cash generation.
Free Cash Flow
Integral Diagnostics Limited produces free cash flow of $26.70M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.07 in free cash annually.
FCF Yield
IDX.AX converts 3.18% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
59.78
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.28
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.24
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.09
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.24
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.63
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.010
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How IDX.AX Stacks Against Its Sector Peers
| Metric | IDX.AX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 59.78 | 28.45 | Worse (Expensive) |
| ROE | 2.05% | 763.00% | Weak |
| Net Margin | 1.83% | -45265.00% (disorted) | Weak |
| Debt/Equity | 1.24 | 0.34 | Weak (High Leverage) |
| Current Ratio | 0.63 | 2795.60 | Weak Liquidity |
| ROA | 0.99% | -16588.00% (disorted) | Weak |
IDX.AX outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Integral Diagnostics Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
50.31%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-86.67%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
-10.68%
Industry Style: Defensive, Growth, Innovation
Declining